Incidence of Vivax Along the Thai Burma Border

• Status: Completed
• Trial end date: 2014-09-02
• Target enrollment: 0
• Participant gender: All

Summary

This is a continuous cohort study consisting of 200 participants (one third 6 months old to 5 years, one third 6 to 15 years old, one third ≥ 15 years old) i.e. a new patient will be recruited (from the same age group) for any patient who develops a Pv infection so that the cohort will always have 200 patients for 3 years. Each patient will be actively followed-up every 8 weeks until Plasmodium vivax infection occurs but the duration of follow up and the number of follow up visits for each patient will vary depending on when or if a vivax infection occurs and when the patient is recruited. Therefore, the minimum follow up period for each patient will be 6 months or time to vivax infection and the maximum will be 3 years if a patient does not get vivax infection and is recruited at the beginning of the study.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oxford
• Collaborator: Mahidol University
• Treatments: Primaquine

Criteria

Inclusion Criteria:

• Asymptomatic adults and children ≥ 6 months

• Documented P.vivax infection in the last 12 months who have not received radical treatment with primaquine

• Weight≥ 7 kg for children

• Participant (or parent/guardian if <18 years old) is willing and able to give written informed consent

• Ability (in the investigators opinion) and willingness of patient or parent/guardian to comply with all study requirements

Exclusion Criteria:

• History of allergy to primaquine

• Medical conditions such as known chronic diseases (TB, HIV, cardio vascular diseases), allergies, mental illnesses and similar conditions that could make the interpretation of symptoms or the follow up difficult.

• Other conditions such as drug addiction, known poor compliance with treatment or follow up.

• Inability to tolerate oral medication

• Pregnancy

• G6PD deficiency

• Blood transfusion in the last 3 months

• Microscopic evidence of Plasmodium vivax, P.falciparum, P. malariae or ovale

• Fever ≥37.5C